Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data ...

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data ...

Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D — potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 - Fractyl Health (NASDAQ:GUTS)

Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs Endoscopic ultrasound-guided delivery achieves targeted pancreatic expression in a large animal model with no toxicity observed to date Data show nutrient-responsive GLP-1 secretion in …

Rejuva Smart GLP-1 pancreatic gene therapy preclinical data highlighting durable potency and safety with limited systemic GLP-1 exposure

New preclinical data from Fractyl Health’s Rejuva smart GLP-1 gene (RJVA-001’s) therapy platform, presented at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, highlight the therapy’s potential to deliver durable, nutrient-responsive GLP-1 secretion from pancreatic beta cells - mimicking natural hormone regulation with low circulating levels of GLP-1 - offering a potentially profound mechanistic advantage over pharmacol…

#A New Dawn for Diabetes Fractyl Unveils Promising Gene Therapy with Long-Lasting Benefits,

'Impending Revolution in Diabetes Treatment: Fractyl Health's Novel Gene Therapy Paves Path for Sustainable Metabolic Management' In an era where the landscape of diabetes management is rapidly evolving, Fractyl Health, Inc. (NASDAQ: GUTS), a pioneer in the field of biotechnology, has recently revealed promising preclinical data surrounding its innovative Rejuva Smart GLP-1 pancreatic gene therapy. Presented at the American Society of Gene & Cel…

Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 17, 2025 07:15 ET  | Source: Fractyl Health, Inc. Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs Endoscopic ultrasound-guided delivery achieves targeted pancreatic expression in a […]